In light of the mounting evidence on the role of FABP5 in cancer cell lines, FABP5 may serve as a novel prognostic marker and inhibiting FABP5 can serve as a potential combinatorial treatment to sensitize mammary carcinoma cells to retinoid therapy. The gene discussed is FABP5; the disease is cancer.